Clinical trials
Uterine Neoplasms trials in the United States with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
38 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2006 | 2 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 1 |
| 2018 | 2 |
| 2020 | 6 |
| 2022 | 2 |
| 2023 | 5 |
| 2024 | 2 |
| 2025 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 26 |
| Recruiting | 5 |
| Active, not recruiting | 3 |
| Terminated | 3 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Northwestern University | 4 |
| Massachusetts General Hospital | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| University of Alabama at Birmingham | 2 |
| University of Michigan | 2 |
| Wake Forest University Health Sciences | 2 |
| Albert Einstein College of Medicine | 1 |
| Case Comprehensive Cancer Center | 1 |
| Dana-Farber Cancer Institute | 1 |
| Dick Domanik | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Uterine Neoplasms | 38 |
| Ovarian Neoplasms | 25 |
| Uterine Cervical Neoplasms | 20 |
| Endometrial Neoplasms | 11 |
| Breast Neoplasms | 9 |
| Neoplasms | 7 |
| Vulvar Neoplasms | 7 |
| Urinary Bladder Neoplasms | 6 |
| Colorectal Neoplasms | 5 |
| Lung Neoplasms | 5 |
Trials
Showing 1 to 25 of 38. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.